Dieter Hoelzer, MD, PhD from the Onkologikum Frankfurt am Museumsufer, Frankfurt, Germany discusses two types of major therapies for acute lymphoblastic leukemia (ALL). The first being for Philadelphia positive patients which includes tyrosine kinase inhibitors combined with low-dose chemotherapy. Immunotherapy, the second type of therapy involves the activation of patient’s own T-cells. Prof. Hoelzer reports encouraging results from both but emphasises the importance of maintaining standards and minimising toxicities when devising and improving therapies. Recorded at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.